Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pinedo

Showing results (331-340 of 569) with videos related to

Pageof 57
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Platelet: transporter of vascular endothelial growth factorH M Verheul, K Hoekman, S Luykx-de Bakker, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1988
Structure-bioactivation relationship of a series of podophyllotoxin derivativesJ M Van Maanen, E van den Akker, J de Vries, et al.
Cancer Research|December 1, 1987
Comparative pharmacokinetics of cisplatin and three analogues in mice and humansM B van Hennik, W J van der Vijgh, I Klein, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
Inactivation of phi X174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213J M van Maanen, C de Ruiter, P R Kootstra, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
5-fluorouracil/leucovorin-induced inhibition of thymidylate synthase in normal tissues of mouse and manC L van der Wilt, C J van Groeningen, H M Pinedo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignanciesJ P Braybrooke, E Boven, N P Bates, et al.
International Journal of Cancer|May 28, 1993
Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolismG J Peters, M Wets, Y P Keepers, et al.
Seminars in Oncology|April 1, 1992
Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorinG J Peters, C J van Groeningen, C L van der Wilt, et al.
Biochemical Pharmacology|September 15, 1994
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell culturesP E Pizao, E Smitskamp-Wilms, J Van Ark-Otte, et al.
Biochemical Pharmacology|May 15, 2007
Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cellsMonique C A Duyndam, Maria P A van Berkel, Josephine C Dorsman, et al.
Pageof 57

Showing results (331-340 of 569) with videos related to

Sort By:
Pageof 57
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Platelet: transporter of vascular endothelial growth factorH M Verheul, K Hoekman, S Luykx-de Bakker, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1988
Structure-bioactivation relationship of a series of podophyllotoxin derivativesJ M Van Maanen, E van den Akker, J de Vries, et al.
Cancer Research|December 1, 1987
Comparative pharmacokinetics of cisplatin and three analogues in mice and humansM B van Hennik, W J van der Vijgh, I Klein, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
Inactivation of phi X174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213J M van Maanen, C de Ruiter, P R Kootstra, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
5-fluorouracil/leucovorin-induced inhibition of thymidylate synthase in normal tissues of mouse and manC L van der Wilt, C J van Groeningen, H M Pinedo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignanciesJ P Braybrooke, E Boven, N P Bates, et al.
International Journal of Cancer|May 28, 1993
Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolismG J Peters, M Wets, Y P Keepers, et al.
Seminars in Oncology|April 1, 1992
Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorinG J Peters, C J van Groeningen, C L van der Wilt, et al.
Biochemical Pharmacology|September 15, 1994
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell culturesP E Pizao, E Smitskamp-Wilms, J Van Ark-Otte, et al.
Biochemical Pharmacology|May 15, 2007
Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cellsMonique C A Duyndam, Maria P A van Berkel, Josephine C Dorsman, et al.
Pageof 57